Mantle cell lymphoma (MCL) is molecularly characterized by bcl-1 rearrangement and cyclin DlIPRAD-1 gene overexpression. Some aggressive variants have been recognized with a blastic or large cell morphology, higher proliferative activity, and shorter survival. p53 gene mutations in lymphoid neoplasms have been detected mainly in high grade lymphomas and have been associated with tumor progression in follicular and small lymphocytic lymphomas. To determine the role of p53 alterations in MCL, we examined 35 typical and 8 aggressive variants (5 blastic and 3 large cell) of MCLs by a combination of immunohistochemistry, single-strand conformational polymorphism analysis of genomic DNA and/or cDNA obtained by reverse transcriptasepolymerase chain reaction, denaturing gradient gel electrophoresis, and sequencing. Of the 8 aggressive MCLs, 3 (38%) contained missense point mutations in exon 8 codon 278 (Pro -+ Leu), exon 8 codon 273 (Arg -+ His), and exon 5 codon 151 (Pro + Ser), respectively. A diffuse p53 protein overexpression was observed in more than 50% of the tumor cells in these 3 cases. A fourth blastic MCL also showed strong p53 immunoreactivity. However, no mutations were de-ANTLE CELL LYMPHOMA (MCL) is a malignant M lymphoproliferative disorder probably derived from naive pregerminal center B-cells. Several studies have identified the t(l1; 14)(q13;q32) translocation and bcl-1 rearrangement as cytogenetic and molecular abnormalities highly characteristic of this lymphoma.'4 This translocation activates the cyclin D1 (PRAD-l/BCL-I/CCNDl) gene located 110-to 130-kb downstream from the major breakpoint of this rearrar~gement.~.' We and others have recently shown that cyclin D1 overexpression occurs in virtually all MCLs independently of the detection of t(l1; 14) translocation or bcl-1 rearrangements.6.8-'0 In addition, overexpression of this gene is a highly specific phenomenon of this type of lymphoma, although it may also occur infrequently in other lymphoproliferative disorders with 1 lq13 translocations.6*8"o Cyclin D1 is a G1 cyclin that participates in the control of the cell cycle progression at the G1-to S-phase transition. Overexpression of this cyclin induces a shortened G 1 phase and less dependence on growth Conversely, the inhibition of cyclin D1 function arrests the cells in Gl.'2-'5 Transfection and transgenic mice experiments have also shown that cyclin D1 may function as an oncogene cooperating with other oncogenes in cellular transf~rmation.'~.'' However, the tumorigenic and transforming properties of cyclin D1 seem to be less effective than those of the conventional oncogenes. The possible additional oncogenic factors cooperating with cyclin D l in the development and progression of MCLs are unknown.
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M lymphoproliferative disorder probably derived from naive pregerminal center B-cells. Several studies have identified the t(l1; 14)(q13;q32) translocation and bcl-1 rearrangement as cytogenetic and molecular abnormalities highly characteristic of this lymphoma.'4 This translocation activates the cyclin D1 (PRAD-l/BCL-I/CCNDl) gene located 110-to 130-kb downstream from the major breakpoint of this rearrar~gement.~.' We and others have recently shown that cyclin D1 overexpression occurs in virtually all MCLs independently of the detection of t(l1; 14) translocation or bcl-1 rearrangements.6.8-'0 In addition, overexpression of this gene is a highly specific phenomenon of this type of lymphoma, although it may also occur infrequently in other lymphoproliferative disorders with 1 lq13 translocations.6*8"o Cyclin D1 is a G1 cyclin that participates in the control of the cell cycle progression at the G1-to S-phase transition. Overexpression of this cyclin induces a shortened G 1 phase and less dependence on growth Conversely, the inhibition of cyclin D1 function arrests the cells in Gl.'2-'5 Transfection and transgenic mice experiments have also shown that cyclin D1 may function as an oncogene cooperating with other oncogenes in cellular transf~rmation.'~.'' However, the tumorigenic and transforming properties of cyclin D1 seem to be less effective than those of the conventional oncogenes. The possible additional oncogenic factors cooperating with cyclin D l in the development and progression of MCLs are unknown.
MCLs may present with a heterogeneous proliferative activity that is considered to be of prognostic significance. In particular, some aggressive variants have been recognized with a blastic or large cell morphology, a high proliferative fraction, and a more aggressive behavior. '8-20 Aggressive variants of MCLs have the same molecular alterations as the tected in exons 5-9 in this case. p53 expression was also detected in 10% of the cells in an additional large cell type of MCL and in less than 1% of the cells in 6 typical cases.
No mutations were detected in any of these cases or in the remaining cases with no expression of the protein. Four nucleotide changes were observed by single-strand conformational polymorphism analysis in 4typical MCLs with no overexpression of the protein. Direct sequencing showed that these nucleotide changes were located at exon 6 (1 case), intron 7 (2 cases), and intron 8 (1 case). The changes in exon 6 and intron 7 were known polymorphisms. The nucleotide change in intron 8 was outside splicing sites of the neighboring exons. The overall survival of the 3 patients with p53 mutations (median, 18.3 months) was significantly shorter than that of pateints with the nonmutated MCLs (median, 49 months; P < .01). These findings indicate that p53 gene mutations are an infrequent phenomenon in MCLs and are associated with a subset of aggressive variants. This is a US government work. There are no restrictions on its use.
classic variants with bcl-1 rearrangements and cyclin D1 overexpression."." However, the proliferative activity of MCLs seems to be independent of the levels of cyclin D1 expression. We have recently shown that the mRNA levels are similar in the classic and aggressive variants of MCLs." These findings indicate that other mechanisms may be implicated in the control of cell cycle progression in MCLs.
p53 is a nuclear phosphoprotein that plays an important role in the regulatory control of the cell cycle. This protein All the cases were reviewed and classified by two pathologists (E.C. and E.S.J.) together. Immunophenotype was analyzed in all cases using immunohistochemistry on frozen tissue sections andor cell suspensions by flow cytometry. These studies included Ig light and heavy chains, several of the Bcell (CD19, CD20, CD22, CD45RA) and T-cell (CD2, CD3, CD5, CD7, CD4, CD8, CD45R0, CD43) markers, and CDlO and CD23.
Cyclin D1 expression was examined in 25 cases, including 5 aggressive variants, by Northern blot analysis, and it was overexpressed in all of them."' All patients had advanced stage disease (111 or IV) and were treated with systemic chemotherapy according to protocols at the respective institutions. Actuarial survival analysis was performed according to the method described by Kaplan & Meier, and the curves were compared by the log-rank test.
Total RNA was isolated from frozen tissues in the 25 cases from HCP by guanidine isothiocyanate extraction and cesium chloride gradient centrifugation." High molecular weight DNA was extracted from the 18 cases from NCI and from additional frozen material available in 19 cases from HCP, using Proteinase WRNAse treatment and phenol-chloroform extraction. DNA and RNA were also extracted from the following cell lines and used as positive controls for p53 mutations during the SSCP, DGGE, and sequencing analysis: MDA-MB-468 breast carcinoma cell line (mutated at codon 273), obtained from the American Tissue Culture Collection (Rockville, MD); the KM12SM colorectal cancer cell line (mutated at codon 179), kindly provided by Dr I.J. Fidler RNA and DNA extraction. For the RNA samples, a nested PCR was used to amplify a fragment of p53 gene including exons 5 through 9. The primers used in PCR procedures are described in Table 1 . The first PCR reaction was performed by mixing 5 p L of the RT reaction product with I U of Taq polymerase (GIBCO-BRL), 0.4 mmoln each primer (1UR and lODN), and PCR buffer ( I O mmoliL Tris-HCI, pH 7.8; SO mmol/L KCI; 1 .5 mmollL MgCI,; and 0.018 gelatin) in a final volume of 25 mL. The reaction was performed for 15 cycles in a thermal cycler (Perkin-Elmer Cetus, Norwalk, CT) at 94°C for 1 minute, at 53°C for 45 seconds, and at 72°C for 1 minute. The second PCR was performed with 0.5 pL of the first reaction in the same conditions but with 120 mmol/L dNTPs and 2 mmol/L of each primer ( 1 26U and 33 I DB2), at an annealing temperature of 5 5 T , and for 35 cycles.
For the DNA samples, 0.5 pg of DNA was added to I U of Tdq, 2 mmoVL each primer (1 2979U and 14875D), I20 mmol/L dNTPs, and PCR buffer in a final volume of 25 pL. The reaction was performed for 25 cycles at 94°C for 45 seconds, at 63°C for 35 seconds, and at 72°C for I minute and 15 seconds. Two nested PCRs were performed on I pL of 1/1,000 dilution of the first PCR product. with two pairs of primers (126U/13463D for exons 5 to 6, and 13966U/331DB2 for exons 7 to 9). The reactions were performed for 3. 5 cycles at 94°C for 45 seconds, at 63°C for 35 seconds, and at 72°C for 1 minute.
SSCP analysis was used to screen for p53 mutations according to a modified protocol of a previously described Nested PCRs were performed as described above in the presence of 2 pCi "P deoxycytidine triphosphate per PCR. For the 37 genomic DNA samples and for the 25 cDNA samples, 5 p L and 9 pL. respectively, of the radioactive PCR product were digested with Hpa 11. Samples were diluted 20-fold in formamide-dye loading buffer,36 incubated for 3 minutes at 95°C. and immediately cooled on ice; 2 pL were loaded on a 6% polyacrylamide nondenaturing gel with or without 10% glycerol. Electrophoresis was performed at room temperature at 30 W for 12 minutes followed by 6 W for 14 hours for IO% glycerol gels and at 30 W for 12 minutes followed by 6 W for 6 hours for the gels without glycerol. The gels were dried under vacuum at 85°C and exposed to an x-ray film at room temperature for 3 days. DGGE analysis was performed in the 37 cases in which genomic DNA was available. Primers flanking p53 exons 5-9 were the same as those described by Beck et except for the exon 8 and 9 primers, and are listed in Table 2 . One primer of each pair was synthesized with an added 40-bp GC-rich sequence (GC clamp) at the 5' end. This results in a high temperature melting domain at one end of each PCR product and renders the remainder of the exon sequence accessible to analysis by DGGE." PCRs were performed using a previously reported protocol with minor modification~.~' Briefly, 200 ng of genomic DNA was mixed with 40 pmol of each primer and 75 nmol of each dNTP in 50 pL of PCR buffer 0.01% gelatin). A total of 1.5 U of Taq was added to each sample, and PCR was performed at 94°C for 1 minute and 15 seconds, at 58°C for 1 minute and 15 seconds, and at 72°C for 35 seconds plus a I-second extension per cycle for 40 cycles. The PCR products were analyzed using a D-gene gel electrophoresis apparatus (Bio-Rad Laboratories, Hercules, CA). Gels were cast using the Model 475 Gradient delivery System (Bio-Rad). Electrophoresis of 40 pL of the PCR product was performed at 150 V at 60°C in 7.5% polyacrylamide gel under the appropriate predetermined denaturing conditions. Except for the gradient conditions for exon 5 (see Table 2 ), all other p53 exons were analyzed under the same gradient conditions described by Beck et al?'
To confirm the possible p53 mutations the samples of DNA with altered migration by SSCP or DGGE were sequenced. Sequences were performed using a commercial cycle sequencing kit (Perkin-Elmer Cetus) and 33P deoxyadenosine triphosphate. A total of 0.5 pL of the nested PCR product was used as template for sequencing. Several internal primers (126U, 331DB2, 13463D, 13966U, 225U, and 5DN) were used for the sequencing reaction at a final concentration of 14 nmol/ L. The reaction was performed according to the instructions of the manufacturer. The reaction was performed for 30 cycles at 94°C for 45 seconds, at 60°C for 30 seconds, and at 72°C for 1 minute and 30 seconds. The final product was diluted twofold in formamidedye loading buffer. Samples were denatured for 3 minutes at 95"C, and 2 pL was analyzed in a denaturing 6% polyacrylamidel8 mol/ L urea sequencing gel for 2 or 3 hours at 55 W. The gels were dried under vacuum at 85°C and exposed to an x-ray film at room temperature for 3 days without an intensifier screen. The presence of a mutation was confirmed by sequencing both the genomic DNA and cDNA of each mutated case, when available, and by sequencing the other DNA strand.
DGGE analysis.
(10 "OK Tris HCI, pH 8.3; 50 "OK KCI; 1.5 "OK MgC12;
Sequencing of the SSCP+ and DGGE+ fragments.
Immunohistochemical analysis. p53 protein expression was immunohistochemically assessed in all cases on formalin-fixed-paraffin-embedded material using the DO-7 (Dako Corp, Carpinteria, CA). In addition, the 25 cases from the HCP were assessed on frozen sections using the anti-p53 monoclonal antibodies (MoAbs) Pab 1801 and Pab 240 (Oncogene Science, Cambridge, MA). The results with the paraffin-embedded material and with the frozen sections in these cases were concordant. Before the application of the primary antibodies on the fixed and paraffin-embedded sections, an antigen retrieval technique was performed. The deparaffinized and rehydrated slides were placed in 10 mmol/L citrate buffer (pH 6) and were heated in the microwave oven for 15 minutes at 700 W. The frozen sections were air-dried, fixed in cold (4°C) acetone for 10 minutes, hydrated, and incubated with the MoAbs. The MoAbs were incubated overnight at 4°C. The immunoreaction was detected by means of the streptavidin-biotin-alkaline phosphatase (Biogenex, San Ramon, CA) technique using Fast-Red as chromogen and levamisole to inhibit endogenous alkaline phosphatase or, alternatively, using the avidin-biotin-peroxidase complex technique (Vectastain ABC kit; Vector Laboratories, Burlinghame, CA) and 3-3' diaminobenzidine tetrahydrochloride (Sigma Chemical Co, St Louis, MO) dissolved in 10 mL of Tris buffer 0.05 mom, pH 7.6, and 0.03% of HzOz as developer. The slides were counterstained with hematoxylin. The cases were evaluated as negative when no positive cells were observed, and p53 was scored as 1+ (weak), 2+ (moderate), and 3+ (strong), when less than 1%, less than 20%, or greater than 20% of the tumor cells, respectively, showed nuclear immunoreactivity.
RESULTS

SSCP and DGGE analysis.
A series of 35 typical and 8 aggressive variants of MCLs were analyzed for the presence of p53 mutations using SSCP of genomic DNA and/or cDNA samples and DGGE of genomic DNA. The results are summarized in Tables 3 and 4 and in Figs 1, 2, and 3 . Only 4 of the 35 typical MCLs and 3 of the 8 aggressive cases showed altered electrophoretic mobility. Two of these aggressive variants (cases no. 10 and 31) had a blastic morphology (Fig 4) , and the third case (case no. 15) was a large cell MCL variant (Fig 5) . In cases no. 10 and 15, the anomalous mobility was found within the fragments encompassing exon 8 using all three techniques, ie, SSCP and DGGE of genomic DNA and SSCP of cDNA. In case no. 31, an abnormally migrating band was identified in exon 5 by SSCP and DGGE t One case with anomalous mobility in the SSCP analysis was the known polymorphism in codon 213. Two cases had a known polymorphism in intron 7, and one case showed a nucleotide change in intron 8 away from splicing sites.
* Histologically aggressive variants defined as blastic (5 cases) or large-cell ("anaplastic"; 3 cases).
of genomic DNA. SSCP analysis of cDNA was not performed in this case because of the unavailability of RNA.
Of the 4 abnormalities found in typical MCLs, 3 occurred only in the SSCP analysis of genomic DNA (cases no. 2, 9, and 38). The anomalous mobility was observed in the fragment containing exons 7-9. This genomic SSCP fragment also contains introns 7 and 8; whereas the other methods used, ie, DGGE and SSCP of cDNA, do not include intronic sequences, suggesting that the abnormalities present were caused by changes in introns 7 or 8. One typical MCL (case no. 4) showed an anomalous band in the exon 6 fragment using all three techniques in a pattern suggestive of the known polymorphism at codon 213.
All the fragments with anomalous SSCP and DGGE were subsequently sequenced. The results are summarized in Table 4 and in Figs 2 and 3. The 3 high grade MCLs showed a missense mutation in exon 8 codon 278 (Pro -+ Leu; case no. lo), exon 8 codon 273 (Arg + His; case no. 15), and exon 5 codon 151 (Pro -+ Ser; case no. 31), respectively. In cases no. 10 and 15, the mutation was confirmed in both genomic DNA and cDNA.
The altered mobility detected in exon 6 in 1 typical MCL (case no. 4) by SSCP and DGGE was shown to be the result of the known polymorphism at codon 213, with the neutral change CGA (Arg) -+ CGG (Arg). This nucleotide change was confirmed in both genomic DNA and cDNA. The anom-
DNA sequencing.
alous SSCP detected at the genomic level in 2 typical MCLs (cases no. 2 and 38) were caused by a known polymorphism in intron 7 characterized by C + T and T + G changes at 71-bp and 91-bp downstream of exon 7, respectively.''' The fourth typical MCL (case no. 9) with an altered mobility detected at genomic level was a nucleotide change in intron 8 (G -+ A), 32-bp downstream of exon 8 (Table 4 and Fig  2) . This nucleotide change was outside splicing sites of the neighboring exons. No DNA from normal tissues of this case was available to rule out the possibility that this change was an intronic polymorphism.
Expression of p53 protein was examined in the 43 cases by immunohistochemistry. The 3 aggressive cases with a missense p53 mutation showed strong nuclear immunostaining in a high proportion of the tumor cells (>SO%; see Figs 4 and 5). The positive cells were diffusely distributed throughout the tumor. In 1 of these cases, a paraffin block of a previous biopsy performed 2 years before was also available. This sample was obtained at the time of presentation of the tumor and was interpreted as a large-cell type of MCL with a nodular growth pattern. Comparing both samples, the second specimen showed a progression to a more aggressive morphology with a diffuse growth pattern and larger and more irregular cells that contained nuclei with blastic chromatin and occasional nucleoli. The mitotic index in the first biopsy specimen was lower (2 mitoses X high power field [HPF] ) than that in the second specimen (6.5 mitoses X HPF). The patient died 2 months after the second biopsy was performed. In spite of the morphological progression between the first and second biopsy specimens, the p53 expression was similar in both samples, with a strong immunoreactivity in more than 70% of the tumor cells.
In addition to the 3 mutated cases described above, 1 blastic MCL (case no. 29) showed strong (3+) p53 overexpression, with nuclear immunoreactivity in more than 50% of cells. However, no gene mutations were detected in exons 5-9 in this case. An additional large-cell type of MCL (case no. 42) showed p53 immunostaining in 10% of the cells. No gene alterations were detected in this case.
None of the remaining nonmutated cases showed overexpression of the protein, including the case with the codon-213 polymorphism and the 3 cases with nucleotide changes in intronic regions. In 6 typical MCLs with no DNA alterImmunohistochemical analysis of' p53 protein. * SSCP analysis of the genomic DNA included exonic and intronic regions, whereas DGGE examined only exonic areas.
For ----
'. I **.'. (D) show the sequences of cases no. 10, 15, 2, and 9, respectively. Cases no. 10 and 15 were mutated in codon 278 and 273. whereas cases no. 2 and 9 showed a nucleotide change in intron 7 and 8 in distant regions of the splicing sites.
For ations, isolated positively stained cells (< 1%) were also observed.
The median overall survival of this series of MCL patients was 42 months (range, 2 to 132 months). Patients with aggressive variants of MCLs had an overall survival (median, 18.3 months; n = 8) significantly shorter than that of patients with typical mantle cell lymphomas (median, 49.8 months; n = 30; P < .02). No follow-up was available in 5 patients with typical MCL. The survival of the 3 patients with p53 mutations (median, 18.3 months) was significantly shorter than that of the pateints with nonmutated MCLs (median, 49 months; 95% confidence interval, 24 to 69 months; P < .01; see (Fig   6) . However, the survival of 5 aggressive MCLs with no detectable p53 mutations was similar to the survival of the mutated aggressive cases (median, 14 and 18.3 months, respectively). The blastic MCL with strong p53 immunostainp53 Alterations and survival qf the patients. ing in which no mutations were detected also had a short survival of 18 months.
DISCUSSION
In this study we have examined 35 typical and 8 aggressive variants of MCLs for the presence of p53 mutations and protein expression. Only 3 of 43 (7%) MCLs showed p53 gene mutations and strong overexpression of the protein. However, all 3 were in the histologically aggressive subgroups, further classified as either blastic or large-cell variants of MCL. None of the typical MCLs with low proliferative fraction and more indolent behavior showed p53 mutations. Protein expression in these cases was negative or negligible. These findings indicate that p53 gene mutations in MCLs are a relatively infrequent phenomenon (7% of all the MCLs examined). However, the presence of mutations in 3 of the 8 histologically aggressive cases (38%) with shortened survival indicates that p53 may be involved in the pathogenesis of a subset of aggressive MCLs.
One of the two mutations found was a G + A transition in codon 273. This is a known hot-spot codon with a CpG dinucleotide. Most of the mutations occurring in this codon, including the one detected in our study, lead to a loss of the biological functions of p53 pr~tein.~" p53 mutations in leukemiadlymphomas, as in other tumors, occur frequently at CpG sites that are considered to be particularly susceptible to spontaneous mutations.24 The other two mutations were C 4 T transitions in codon 278 and 151. Mutations in these codons are rare in lymphomas but have been detected in several lymphomas and hematologic d i s~r d e r s .~~~~~~~"~~' Three other nucleotide changes were detected in intronic regions of the gene. Two of them were a known polym~rphism,~~ and, in the third case, the change was distant from splicing sites.
The immunohistochemical detection of p53 protein in a high number of cells (>50%) was relatively concordant with the presence of gene mutations in this series of MCLs because strong p53 immunostaining was observed in the 3 cases with p53 gene mutations, whereas all typical MCLs For personal use only. on October 31, 2017. by guest www.bloodjournal.org From were negative or weakly positive. However, no mutations were detected in exons 5-9 in 2 blastic MCLs with strong (case no. 29) and moderate (case no. 42) pS3 overexpression, respectively. Immunohistochemical detection of pS3 protein in human tumors has been considered to be a consequence of the gene mutation and protein stabilization with a longer half-life. However, several studies have now shown that in some high grade non-Hodgkin's lymphomas (NHLs), p53 overexpression is not always associated with detectable gene mutations.'X.J'.." Although we can not completely rule out the existence of mutations in our 2 blastic MCLs overexpressing the protein. mutations in regions outside of exons 5 to 9 in NHL seem to be rare." The increased expression of the protein in these cases may be caused by nondetected mutations or by the stabilization of the protein by other mechanisms, or, alternatively, it may be related to the high proliferative activity of tumor cells. Overexpression of wildtype p53 has been observed in highly proliferating cells and reactive tissues in which it may represent a normal expression related to its function in the control of cell proliferation.?x.41.15
The presence of pS3 mutations in aggressive MCLs is consistent with the observations in other hematopoietic disorders and NHLs in which pS3 mutations mainly occur in high grade tumors and in association with progression of the disease. In particular, pS3 alterations are rarely found in low grade lymphomas and indolent chronic lymphocytic leukemias. However, mutations are detected in high grade lymphomas evolving from B-cell chronic lymphocytic leukemia (Richter's syndrome) and in transformed follicular lymphomas, suggesting that pS3 mutations may be implicated in the histological progression of these tumors.25.~s.'0ac' Similar to those in follicular lymphomas, pS3 mutations were only present in less than half of the blastic and large-cell types of MCLs, indicating that other mechanisms may also be implicated in the pathogenesis of these aggressive variants.
MCLs are considered indolent lymphomas with frequent relapses and an intermediate overall survival (median, 3 to 5 years) between low and high grade NHL." Histological progression from typical MCLs to more aggressive variants may occur in tumor relapses. with an increase in the mitotic index, nuclear size, and chromatin dispersal.47 However, most aggressive variants of MCL are recognized at diagnosis, indicating that they may arise de novo as primary aggressive MCLs." In our series, the 8 aggressive cases were diagnosed at presentation. In 1 of these cases, a further morphological progression was observed at relapse after an interval of 24 months. In this tumor, the p53 mutation was found in the second biopsy specimen. Although no molecular studies could be performed in the first biopsy specimen of this patient, the strong overexpression of the protein with an intensity similar to that of the second sample suggests that p53 was already mutated at presentation. Similarly, the p53 mutations observed in the other 2 blastic MCLs were also detected during biopsies performed at diagnosis. These findings suggest that p53 mutations in MCLs may occur in an early stage of the development of these aggressive variants of the tumors. This model seems to be different from that observed in follicular lymphomas, in which p53 mutations appear during the evolution of the tumor and are closely associated with its histological transformation to a high grade lymphoma. 29 The mechanisms by which p53 mutations may lead to the higher proliferative activity and more aggressive behavior of this subset of MCLs are not clear. Wild-type p53 participates in the control of cell cycle progression, particularly in a G1 checkpoint that allows the cell to repair DNA damage before progression in the cell cycle.2',22 Inactivation of p53 may favor the accumulation of other genetic lesions that would confer to the cells a selective growth advantage.
In conclusion, our findings indicate that p53 gene alterations are an infrequent phenomenon in MCLs, but that they are associated with a subset of aggressive variants and short survival. Further studies are needed to clarify other possible molecular mechanisms implicated in the pathogenesis of the aggressive MCLs in which no p53 mutations are detected.
